TY - JOUR
T1 - Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy
T2 - Effect of number of metastatic lymph nodes and lymph node ratio
AU - Asiyanbola, Bolanle
AU - Gleisner, Ana
AU - Herman, Joseph M.
AU - Choti, Michael A.
AU - Wolfgang, Christopher L.
AU - Swartz, Michael
AU - Edil, Barish H.
AU - Schulick, Richard D.
AU - Cameron, John L.
AU - Pawlik, Timothy M.
N1 - Funding Information:
Acknowledgments Dr. Pawlik is supported by Grant Number 1KL2RR025006-01 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. The contents of the publication are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH.
PY - 2009/4
Y1 - 2009/4
N2 - Background: There are limited data on patterns of recurrence and factors associated with local recurrence following pancreaticoduodenectomy for pancreatic adenocarcinoma and adjuvant 5-flurouracil-based chemoradiation therapy. Methods and Materials: Between 1995 and 2005, 905 patients underwent pancreaticoduodenectomy for pancreatic adenocarcinoma; 154 patients had complete pattern of recurrence data available. Results: At median follow-up of 20.2 months, 103 (66.9%) patients recurred with median time to recurrence of 16.2 months. Most patients recurred with distant disease only (68.9%), while 21.4% patients recurred with local disease only; ten (9.7%) patients recurred with local and distant disease. Several factors were associated with local recurrence: poor tumor differentiation (hazards ration [HR] 2.39) and presence of metastatic lymph nodes (HR 1.89, both p∈<∈0.05). Among N1 patients, poor tumor differentiation (HR 3.92), >5 metastatic LN (HR 3.75), and lymph node ratio (LNR) >0.4 (HR 2.96) had the highest risk of local recurrence (all p∈<∈0.05). Increasing LNR was associated with an incremental increased risk of local recurrence (LNR <0.2, 21.3% versus LNR 0.2 to 0.4, 25.2% versus LNR >0.4, 40.4%; p∈<∈0.05). Conclusions: Although most patients who receive standard 5-flurouracil-based chemoradiation therapy will ultimately succumb to distant disease, about 30% recur locally. Poor tumor differentiation, a high number of metastatic LN (>5), and LNR >0.4 are associated with the highest risk of local failure. In these patients, radiation dose escalation and/or a combination of radiation with novel chemotherapeutic agents may be necessary to improve outcomes.
AB - Background: There are limited data on patterns of recurrence and factors associated with local recurrence following pancreaticoduodenectomy for pancreatic adenocarcinoma and adjuvant 5-flurouracil-based chemoradiation therapy. Methods and Materials: Between 1995 and 2005, 905 patients underwent pancreaticoduodenectomy for pancreatic adenocarcinoma; 154 patients had complete pattern of recurrence data available. Results: At median follow-up of 20.2 months, 103 (66.9%) patients recurred with median time to recurrence of 16.2 months. Most patients recurred with distant disease only (68.9%), while 21.4% patients recurred with local disease only; ten (9.7%) patients recurred with local and distant disease. Several factors were associated with local recurrence: poor tumor differentiation (hazards ration [HR] 2.39) and presence of metastatic lymph nodes (HR 1.89, both p∈<∈0.05). Among N1 patients, poor tumor differentiation (HR 3.92), >5 metastatic LN (HR 3.75), and lymph node ratio (LNR) >0.4 (HR 2.96) had the highest risk of local recurrence (all p∈<∈0.05). Increasing LNR was associated with an incremental increased risk of local recurrence (LNR <0.2, 21.3% versus LNR 0.2 to 0.4, 25.2% versus LNR >0.4, 40.4%; p∈<∈0.05). Conclusions: Although most patients who receive standard 5-flurouracil-based chemoradiation therapy will ultimately succumb to distant disease, about 30% recur locally. Poor tumor differentiation, a high number of metastatic LN (>5), and LNR >0.4 are associated with the highest risk of local failure. In these patients, radiation dose escalation and/or a combination of radiation with novel chemotherapeutic agents may be necessary to improve outcomes.
KW - 5-Flurouracil
KW - Adenocarcinoma
KW - Adjuvant chemoradiation
KW - Lymph node
KW - Pancreatic
KW - Recurrence
UR - http://www.scopus.com/inward/record.url?scp=67349233391&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67349233391&partnerID=8YFLogxK
U2 - 10.1007/s11605-008-0762-x
DO - 10.1007/s11605-008-0762-x
M3 - Article
C2 - 19089517
AN - SCOPUS:67349233391
SN - 1091-255X
VL - 13
SP - 752
EP - 759
JO - Journal of Gastrointestinal Surgery
JF - Journal of Gastrointestinal Surgery
IS - 4
ER -